scholarly journals Low‐ and high‐dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open‐label study

2019 ◽  
Vol 34 (3) ◽  
pp. e2696 ◽  
Author(s):  
Sho Horikoshi ◽  
Itaru Miura ◽  
Mizue Ichinose ◽  
Shinnosuke Yamamoto ◽  
Masashi Ito ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Plasma Levels ◽  
Homovanillic Acid ◽  
High Dose ◽  
Open Label ◽  
Major Depressive ◽  
Open Label Study ◽  
Label Study

Low and high dose aripiprazole augmentation in major depressive disorder: a randomised, open-label study

2017 ◽  
Vol 27 ◽  
pp. S861 ◽  
Author(s):  
S.H. Horikoshi ◽  
I.M. Miura ◽  
S.Y. Yamamoto ◽  
O.A. Abe ◽  
M.I. Ito ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
High Dose ◽  
Open Label ◽  
Major Depressive ◽  
Open Label Study ◽  
Label Study

scholarly journals Duloxetine in the treatment of major depressive disorder: an open-label study

2007 ◽  
Vol 7 (1) ◽  
Author(s):  
James I Hudson ◽  
David G Perahia ◽  
Inmaculada Gilaberte ◽  
Fujun Wang ◽  
John G Watkin ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Open Label ◽  
Major Depressive ◽  
Open Label Study ◽  
Label Study

scholarly journals Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study

2016 ◽  
Vol 29 (2) ◽  
pp. 72-79 ◽  
Author(s):  
Shinsuke Hidese ◽  
Miho Ota ◽  
Chisato Wakabayashi ◽  
Takamasa Noda ◽  
Hayato Ozawa ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cognitive Functions ◽  
Verbal Memory ◽  
Rating Scale ◽  
Stroop Test ◽  
Open Label ◽  
Major Depressive ◽  
Open Label Study ◽  
Label Study

Objectivel-theanine, an amino acid uniquely contained in green tea (Camellia sinensis), has been suggested to have various psychotropic effects. This study aimed to examine whether l-theanine is effective for patients with major depressive disorder (MDD) in an open-label clinical trial.MethodsSubjects were 20 patients with MDD (four males; mean age: 41.0±14.1 years, 16 females; 42.9±12.0 years). l-theanine (250 mg/day) was added to the current medication of each participant for 8 weeks. Symptoms and cognitive functions were assessed at baseline, 4, and 8 weeks after l-theanine administration by the 21-item version of the Hamilton Depression Rating Scale (HAMD-21), State-Trait Anxiety Inventory (STAI), Pittsburgh Sleep Quality Index (PSQI), Stroop test, and Brief Assessment of Cognition in Schizophrenia (BACS).ResultsHAMD-21 score was reduced after l-theanine administration (p=0.007). This reduction was observed in unremitted patients (HAMD-21>7; p=0.004) at baseline. Anxiety-trait scores decreased after l-theanine administration (p=0.012) in the STAI test. PSQI scores also decreased after l-theanine administration (p=0.030) in the unremitted patients at baseline. Regarding cognitive functions, response latency (p=0.001) and error rate (p=0.036) decreased in the Stroop test, and verbal memory (p=0.005) and executive function (p=0.016) were enhanced in the BACS test after l-theanine administration.ConclusionOur study suggests that chronic (8-week) l-theanine administration is safe and has multiple beneficial effects on depressive symptoms, anxiety, sleep disturbance and cognitive impairments in patients with MDD. However, since this is an open-label study, placebo-controlled studies are required to consolidate the effects.

Sign in / Sign up

Export Citation Format

Share Document